Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2016

View Archived Issues

University of Queensland to develop a more accessible rotavirus vaccine

Rational Vaccines to start a phase I trial of Theravax HSV-2

ERO1LB shows promise as a therapeutic target for type 2 diabetes

Eisai submits label change application to FDA for antiepileptic drug Fycompa

Dicerna Pharmaceuticals to focus resources on GalXC technology platform

NASH FX trial of GR-MD-02 for NASH with advanced fibrosis does not meet primary biomarker endpoint

GM-CSF shows potential as a therapeutic target in multiple sclerosis

Actinium Pharmaceuticals starts phase II trial of Actimab-A in patients with AML

Takeda obtains NDA approval for Inisync fixed-dose combination tablets in Japan

IND submission for phase II trial of elafibranor in primary biliary cholangitis

Vectus Biosystems patents vasodilating agents

NCI awards SBIR contract to Cellerant Therapeutics

Pronai Therapeutics obtains exclusive license for PNT-737 from the CRT Pioneer Fund

Marketing approval for Galderma's Epiduo given by several European regulatory bodies

Pharmakea discloses ENPP2 inhibitors

French scientists describe FGFR3 inhibitors

DoD grant supports cardiac cell therapy trial in HFpEF

Merck & Co. develops IRAK-4 inhibitors

Medigene and bluebird bio collaborate on TCR immunotherapies

Enanta begins phase I trial of FXR agonist EDP-305 for NASH

FDA approves Orkambi for younger cystic fibrosis population

EGFL7 modulation shows potential for the treatment of MS and EAE

FDA places clinical hold on INDs for Alcobra's metaxodine

Parkinson's disease vaccine Affitope(R) PD-01A is boostable

Evotec signs collaboration with C4X Discovery Holdings

VSN-16R ameliorates spasticity without sedation in a MS model

Pernix announces U.S. distribution of Treximet for pediatric migraine patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...